AKT1 and cancer: Given the significant roles of the EGFR/PI3K/AKT/mTOR pathway in human cancer, there has been a strong emphasis on investigating its clinical potential by targeting the major components of the EGFR/PI3K/AKT/mTOR signaling pathway using specific small-molecule inhibitors.